From our Annual Public Meeting to topic-specific convenings, the Reagan-Udall Foundation for the FDA brings stakeholders together on matters critical to regulatory science and practice. These events, often hosted at the request of FDA leadership, provide space for expert analysis and candid discussion on FDA’s priority issues. See below for upcoming events.

Upcoming Events

Global Harmonization for Data Access & Exchange

To meet patient needs, global medical product development must move toward efficient, coordinated international regulatory submission and review of medical products - bringing high-quality drugs to market faster without compromising safety or effectiveness.

Automation Basics: Virtual Discussion

Join us to hear from outsourcing facility executives and consultants about incorporating automation in your outsourcing facility’s processes and procedures.

2026 Innovations in Regulatory Science & Policy Awards

Join us for our 10th annual Awards celebration!

Integrating Automation for Quality Outcomes: Virtual Discussion

Hear from outsourcing facility executives and consultants who will share their perspectives on how they manage change as they balance incorporating automation with promoting quality and maintaining current good manufacturing practice requirements.

Generic Drug Quality, Safety, and Efficacy

Join us on Feb. 19 for a hybrid public meeting to explore the oversight of generic drugs and the perceptions that shape confidence in generic drugs

Past Events

Rare Disease Framework Initiative Public Meeting

Hybrid public meeting to seek input related to the FDA’s Rare Disease Framework Initiative to reimagine the agency’s approach to rare disease drug development.

Patient Voice in Rare Disease Medical Product Development

The Foundation, in collaboration with the FDA, convened a hybrid public meeting to explore the patient voice in rare disease medical product development (biologic, drug, and device).

Quality Beyond the Quality Unit: Virtual Quality Discussion

Join us for a discussion with outsourcing facility executives and consultants on how to embed quality across the organization.

Addressing the Public Health Effects of Opioid Medications

The Foundation, in collaboration with the FDA, will convene a hybrid meeting to hear public comments on perspectives regarding the use of opioid medications for the management of pain and addiction.

Developing a Product Portfolio: Virtual Outsourcing Facility Discussion

Our discussion with outsourcing facility executives and a group purchasing organization covered developing a portfolio, including how to maintain and evolve a portfolio and how customer relationships and operational capacity factor into decision making.

Expanded Access: Insights & Resources

This informational webinar offered a “101-level” overview of how the expanded access process works.

Drug Repurposing: Considerations for Selection Criteria and Prioritization

The Foundation, in collaboration with the U.S. Food and Drug Administration, convened a hybrid public meeting to discuss opportunities to expand treatment options for patients by identifying new uses for approved drugs.

2026 Annual Public Meeting

Each year, the Reagan-Udall Foundation for the FDA’s Board of Directors conducts an annual public meeting to highlight the Foundation’s activities in support of the U.S. Food and Drug Administration.

Affecting the Aging Trajectory: Regulatory Constructs for Gerotherapeutic Drug, Biologic & Device Development

On May 27, 2026, the Reagan-Udall Foundation for the FDA convened a hybrid public meeting on Exploring Regulatory Constructs for Gerotherapeutic Drug Development to discuss potential regulatory constructs.

Over-the-Counter Diagnostics: Advancing Home as a Health Care Hub

With the growing public appreciation of accessible health care solutions, this public meeting fostered collaboration, explored critical gaps, and illuminated pathways for the development, review, and deployment of at-home diagnostic devices to improve health care access, and advance the home as a hub of health care.